The need and the type of adjuvant breast cancer drug therapy mainly depends on tumor size, lymph node status, grading, hormone-receptor status, human epidermal growth factor 2 (HER2) status, menopausal status and age [12,13]. This evidence concerns the gene ERBB2 and breast carcinoma.